Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism
- 4 October 2018
- journal article
- research article
- Published by BMJ in Journal of Medical Genetics
- Vol. 56 (1) , 39-42
Abstract
Background: Immune checkpoint inhibitor therapy is a modern breakthrough in medical oncology, but it can precipitate inflammatory and autoimmune adverse effects. Among the most serious of these toxicities is haemophagocytic lymphohistiocytosis (HLH), a life-threatening disorder of unbridled immune activation that results in injury to multiple organ systems. Objective: Description of a case of pembrolizumab-associated HLH in a patient with a proposed underlying genetic risk factor for its occurrence. Methods and results: We describe a patient with aggressive metastatic breast cancer who developed HLH while undergoing experimental treatment with pembrolizumab, resulting in critical illness and multiorgan system failure. Pembrolizumab discontinuation and high-dose corticosteroids were effective in managing HLH. Subsequent next-generation sequencing of 15 genes associated with HLH revealed a germline polymorphism in perforin-1 ( PRF1 ), PRFA91V , that may have predisposed the patient to develop HLH. The patient has had no evidence of malignancy for 2 years following recovery despite receiving no further cancer-directed treatment. Conclusions: HLH is a rare but serious complication of immune checkpoint blockade. Patients with underlying hypomorphic alleles in PRF1 may be predisposed to develop this toxicity. Further studies are necessary to confirm a possible link between perforin gene mutations and immune checkpoint blockade-associated HLH.Keywords
This publication has 27 references indexed in Scilit:
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint InhibitorsJAMA Oncology, 2016
- Spectrum of Atypical Clinical Presentations in Patients with Biallelic PRF1 Missense MutationsPediatric Blood & Cancer, 2015
- Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic SyndromeArthritis & Rheumatology, 2014
- Familial and Acquired Hemophagocytic LymphohistiocytosisAnnual Review of Medicine, 2012
- Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocolBlood, 2011
- How I treat hemophagocytic lymphohistiocytosisBlood, 2011
- Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and managementClinical and Experimental Immunology, 2011
- Familial haemophagocytic lymphohistiocytosis in patients who are heterozygous for the A91V perforin variation is often associated with other genetic defectsInternational Journal of Immunogenetics, 2007
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006
- A91V perforin variation in healthy subjects and FHLH patientsInternational Journal of Immunogenetics, 2006